

US009757191B2

### (12) United States Patent

Avitall et al.

### (10) Patent No.: US 9,757,191 B2

(45) **Date of Patent:** \*Sep. 12, 2017

### (54) ELECTROPHYSIOLOGY SYSTEM AND METHODS

(71) Applicant: **Boston Scientific Scimed Inc.**, Maple

Grove, MN (US)

(72) Inventors: Boaz Avitall, Whitefish Bay, WI (US);

Josef V. Koblish, Sunnyvale, CA (US)

(73) Assignee: Boston Scientific Scimed, Inc., Maple

Grove, MN (US)

(\*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 84 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 14/498,211

(22) Filed: Sep. 26, 2014

(65) **Prior Publication Data** 

US 2015/0011995 A1 Jan. 8, 2015

#### Related U.S. Application Data

(63) Continuation of application No. 13/738,562, filed on Jan. 10, 2013, now Pat. No. 8,876,817.

(Continued)

(51) **Int. Cl.** 

**A61B 18/12** (2006.01) **A61B 18/14** (2006.01)

(Continued)

(52) U.S. Cl.

CPC ....... A61B 18/1492 (2013.01); A61B 5/0422 (2013.01); A61B 5/6852 (2013.01);

(Continued)

(58) Field of Classification Search

CPC . A61B 18/1206; A61B 18/1492; A61B 18/18; A61B 2018/0016;

(Continued)

### (56) References Cited

#### U.S. PATENT DOCUMENTS

3,773,401 A 11/1973 Douklias et al. 4,466,443 A 8/1984 Utsugi

(Continued)

#### FOREIGN PATENT DOCUMENTS

CA 2682055 A1 10/2008 CA 2847846 A1 3/2013 (Continued)

### OTHER PUBLICATIONS

Goldberg, S. Nahum et al., "Variables Affecting Proper System Grounding for Radiofrequency Ablation in an Animal Model", JVIR, vol. 11, No. 8, Sep. 2000, pp. 1069-1075.


(Continued)

Primary Examiner — Daniel Fowler (74) Attorney, Agent, or Firm — Faegre Baker Daniels LLP

### (57) ABSTRACT

An electrophysiology system comprises an ablation catheter, a radiofrequency generator, and a mapping processor. The ablation catheter has a tissue ablation electrode and a plurality of microelectrodes distributed about the circumference of the tissue ablation electrode and electrically isolated therefrom. The plurality of microelectrodes define a plurality of bipolar microelectrode pairs. The mapping processor is configured to acquire output signals from the bipolar microelectrode pairs, compare the output signals, and generate an output to a display providing a visual indication of a characteristic of the microelectrodes and the tissue ablation electrode relative to myocardial tissue to be mapped and/or ablated.

### 13 Claims, 14 Drawing Sheets



#### 5,573,535 A 5,575,772 A Related U.S. Application Data 11/1996 Viklund 11/1996 Lennox 5,579,764 A 12/1996 Goldreyer (60) Provisional application No. 61/585,083, filed on Jan. 5.582,609 A 12/1996 Swanson et al. 10, 2012, provisional application No. 61/715,032, 5,647,870 A 7/1997 Kordis et al. filed on Oct. 17, 2012. 5,718,701 A 2/1998 Shai et al. 5,722,402 A 3/1998 Swanson et al. 5,762,067 A 6/1998 Dunham et al. (51) Int. Cl. 5,788,636 A 8/1998 Curley A61B 18/18 (2006.01)5.792.064 A 8/1998 Panescu et al. A61B 5/042 (2006.01)5,800,482 A 9/1998 Pomeranz et al. A61B 5/00 (2006.01)5,820,568 A 10/1998 Willis A61B 18/00 (2006.01)5,830,213 A 11/1998 Panescu et al. 5,833,621 A 11/1998 Panescu et al. A61B 5/0464 (2006.01)5,836,990 A 11/1998 A61B 5/06 (2006.01)Lafontaine 5,868,735 A 2/1999 (52) U.S. Cl. 5,871,483 A 2/1999 Jackson et al. CPC ...... A61B 18/1206 (2013.01); A61B 18/18 5,871,526 A 2/1999 Gibbs et al. 5,876,336 A 3/1999 Swanson et al. (2013.01); A61B 5/0464 (2013.01); A61B 5.885,278 A 3/1999 Fleischman *5/065* (2013.01); *A61B 5/4887* (2013.01); 5,913,856 A 6/1999 Chia et al. A61B 2018/0016 (2013.01); A61B 2018/00357 5,916,213 A 6/1999 Haissaguerre et al. (2013.01); A61B 2018/00577 (2013.01); A61B 5,957,850 A 9/1999 Marian et al. 2018/00642 (2013.01); A61B 2018/00654 6,004,269 A 12/1999 Crowley et al 6,027,500 A 2/2000 Buckles et al. (2013.01); A61B 2018/00678 (2013.01); A61B 6,050,267 A 4/2000 Nardella et al. 2018/00839 (2013.01); A61B 2018/00898 6,050,994 A 4/2000 Sherman (2013.01); A61B 2018/00904 (2013.01); A61B 6,059,778 A 5/2000 Sherman 2018/00916 (2013.01); A61B 2018/126 6.063.078 A 5/2000 Wittkampf 5/2000 6,064,905 A (2013.01); A61B 2218/002 (2013.01) Webster, Jr. et al. 6,068,629 A 5/2000 Haissaguerre et al. (58) Field of Classification Search 6,070,094 A 5/2000 Swanson et al. CPC A61B 2018/00351; A61B 2018/00577; A61B 6,083,170 A 7/2000 Ben-Haim 2018/00642; A61B 2018/00654; A61B 6,083,222 A 7/2000 Klein et al 2018/00678; A61B 2018/00839; A61B 6,099,524 A 8/2000 Lipson et al. 6,101,409 A 8/2000 Swanson et al. 2018/00898; A61B 2018/00904; A61B 6,116,027 A 9/2000 Smith et al. 2018/00916; A61B 2018/126; A61B 6,120,476 A 9/2000 Fung et al. 2218/002; A61B 5/0422; A61B 5/0464; 12/2000 6,165,123 A Thompson A61B 5/065; A61B 5/4887; A61B 5/6852 6,171,305 B1 1/2001 Sherman 6,200,314 B1 3/2001 Sherman See application file for complete search history. 6,206,831 B1 3/2001 Suorsa et al. 6,210,337 B1 4/2001 Dunham et al. (56)References Cited 6,216,027 B1 4/2001 Willis et al. 6,224,557 B1 5/2001 Ziel et al. U.S. PATENT DOCUMENTS 6,233,491 B1 5/2001 Kordis et al. 6,241,754 B1 6/2001 Swanson et al. 4.602.624 A 7/1986 Naples et al. 6,270,493 B1 8/2001 Lalonde et al. 1/1987 4,633,882 A Matsuo et al. 6,290,697 B1 9/2001 Tu et al. 3/1988 4,732,149 A Sutter 6,352,534 B1 3/2002 Paddock et al. 4,763,660 A 8/1988 Kroll et al. 6,395,325 B1 5/2002 Hedge et al. 4,966,145 A 10/1990 Kikumoto et al. 6,400,981 B1 6/2002 Govari 5,019,076 A 5/1991 Yamanashi et al. 6,423,002 B1 7/2002 Hossack 5,029,588 A 7/1991 Yock et al. 6,475,213 B1 11/2002 Whayne et al. 5,178,150 A 1/1993 Silverstein et al. 6,488,678 B2 12/2002 Sherman 5,217,460 A 6/1993 Knoepfler 6,491,710 B2 12/2002 Satake 5.238.004 A 8/1993 Sahatjian et al. 6,508,767 B2 1/2003 Burns et al. 5,240,003 A 8/1993 Lancee et al. 6,508,769 B2 1/2003 Bonnefous 5,254,088 A 10/1993 Lundquist et al. 6,508,803 B1 1/2003 Horikawa et al. 5,295,482 A 3/1994 Clare et al. 6,516,667 B1 2/2003 Broad et al. 5,318,589 A 6/1994 Lichtman 6,517,533 B1 2/2003 Swaminathan 5,324,284 A 6/1994 Imran 6,517,534 B1 2/2003 McGovern et al. 5,331,966 A 7/1994 Bennett et al. 6,537,271 B1 3/2003 Murray et al. 5,334,193 A 8/1994 Nardella 6,544,175 B1 4/2003 Newman 5,341,807 A 8/1994 Nardella 6,546,270 B1 4/2003 Goldin et al. 1/1995 5,377,685 A Kazi et al. 6.547.788 B1 4/2003 Maguire et al. 5,383,874 A 1/1995 Jackson et al. 6,569,160 B1 5/2003 Goldin et al. 5,385,146 A 1/1995 Goldrever 6,572,547 B2 6/2003 Miller et al 1/1995 5,385,148 A Lesh et al 6,575,966 B2 6/2003 Lane et al. 5,391,199 A 2/1995 Ben-Haim 6,575,969 B1 6/2003 Rittman, III et al. 5,398,683 A 3/1995 Edwards et al. 6.579.278 B1 6/2003 Bencini 5,423,811 A 6/1995 Imran et al. 6,582,372 B2 6/2003 Poland 5,447,529 A 9/1995 Marchlinski et al. 6,584,345 B2 6/2003 Govari 5.462.521 A 10/1995 Brucker et al. 6,589,182 B1 7/2003 Loftman et al. 5,482,054 A 1/1996 Slater et al. 6,592,525 B2 7/2003 Miller et al 5,485,849 A 1/1996 Panescu et al. 6,602,242 B1 8/2003 Fung et al. 2/1996 5,494,042 A Panescu et al 6,620,103 B1 9/2003 Bruce et al. 5,500,012 A 3/1996 Brucker et al. 6,632,179 B2 Wilson et al. 10/2003 5,520,683 A 5/1996 Subramaniam et al. 5,571,088 A 11/1996 Lennox et al. 6,638,222 B2 10/2003 Chandrasekaran et al.

# US 9,757,191 B2 Page 3

(56)	R	eferen	ces Cited	7,720,420		5/2010	
	U.S. PA	TENT	DOCUMENTS	7,727,231 7,736,362	B2	6/2010	Swanson Eberl et al.
6 6 40 120	D1 1/	1/2002	Cryoman at al	7,740,629 7,758,508			Anderson et al. Thiele et al.
6,640,120 6,647,281			Swanson et al. Morency	7,766,833			Lee et al.
6,656,174			Hegde et al.	7,776,033			Swanson
6,658,279			Swanson et al.	7,785,324 7,794,398		8/2010 9/2010	
6,663,573 6,666,862			Goldin Jain et al.	7,796,789			Salgo et al.
6,676,606			Simpson et al.	7,799,025	B2	9/2010	Wellman
6,692,441	B1 2	2/2004	Poland et al.	7,815,572		10/2010	
6,705,992 6,709,396			Gatzke Flesch et al.	7,819,863 7,837,624			Eggers et al. Hossack et al.
6,709,390			Gilboa et al.	7,859,170			Knowles et al.
6,719,756			Muntermann	7,862,561			Swanson et al.
6,735,465			Panescu	7,862,562 7,879,029		1/2011	Jimenez
6,736,814 6,743,174			Manna et al. Ng et al.	7,892,228			Landis et al.
6,773,402			Govari et al.	7,894,871			Wittkampf et al.
6,776,758			Peszynski et al.	7,918,850 7,957,817			Govari et al. Gillespie et al.
6,796,979 6,796,980		9/2004 9/2004		7,996,085		8/2011	
6,804,545			Fuimaono et al.	8,016,822	B2	9/2011	Swanson
6,811,550	B2 1	1/2004	Holland et al.	8,048,028			Horn et al.
6,824,517			Salgo et al.	8,103,327 8,128,617			Harlev et al. Bencini et al.
6,837,884 6,845,257			Woloszko Fuimaono et al.	8,160,690			Wilfley et al.
6,845,264			Skladnev et al.	8,162,935	B2		Paul et al.
6,917,834			Koblish et al.	8,265,745 8,267,926			Hauck et al. Paul et al.
6,922,579 6,923,808			Taimisto et al. Taimisto	8,290,578			Schneider
6,932,811			Hooven et al.	8,317,783	B2	11/2012	Cao et al.
6,945,938	B2 9	9/2005	Grunwald	8,369,922			Paul et al.
6,950,689			Willis et al.	8,400,164 8,403,925			Osadchy et al. Miller et al.
6,952,615 6,958,040			Satake Oliver et al.	8,406,866			Deno et al.
7,001,383			Keidar	8,414,579			Kim et al.
7,037,264			Poland	8,449,535 8,454,538			Deno et al. Wittkampf et al.
7,047,068 7,097,643			Haissaguerre Cornelius et al.	8,454,589			Deno et al.
7,097,043			Fuimaono et al.	8,489,184	B2	7/2013	Wilfley et al.
7,105,122			Karason	8,579,889 8,583,215		11/2013	Bencini Lichtenstein
7,112,198			Satake Swanson et al.	8,603,084			Fish et al.
7,115,122 7,123,951			Fuimaono et al.	8,603,085	B2	12/2013	
7,131,947	B2 1	1/2006	Demers	8,644,950		2/2014	
7,166,075			Varghese et al.	8,657,814 8,672,936			Werneth et al. Thao et al.
7,181,262 7,220,233			Fuimaono et al. Nita et al.	8,679,109	B2		Paul et al.
7,232,433	B1 6	5/2007	Schlesinger et al.	8,728,077			Paul et al.
7,247,155			Hoey et al.	8,740,900 8,755,860			Kim et al. Paul et al.
7,270,634 7,288,088			Scampini et al. Swanson	8,771,343			Weber et al.
7,291,142			Eberl et al.	8,894,643			Watson et al.
7,306,561			Sathyanarayana	8,906,011 8,945,015			Gelbart et al. Rankin et al.
7,335,052 7,347,820		2/2008	D'Sa Bonnefous	8,998,890			Paul et al.
7,347,821			Skyba et al.	9,089,340			Hastings et al.
7,347,857			Anderson et al.	9,125,565 9,125,668		9/2015	Hauck Subramaniam et al.
7,361,144 7,422,591		4/2008 9/2008	Levrier et al.	9,123,008			Deno et al.
7,422,391		0/2008		9,211,156		12/2015	Kim et al.
7,455,669	B2 11	1/2008	Swanson	9,241,687		1/2016	McGee Rankin et al.
7,488,289			Suorsa et al.	9,241,761 9,254,163			Paul et al.
7,507,205 7,519,410			Borovsky et al. Taimisto et al.	9,271,782			Paul et al.
7,529,393			Peszynski et al.	9,283,026			Paul et al.
7,534,207			Shehada et al.	9,393,072 2001/0029371		7/2016 10/2001	Kim et al.
7,544,164 7,549,988			Knowles et al. Eberl et al.	2001/0029371			Koblish et al.
7,569,052			Phan et al.	2002/0165448			Ben-Haim et al.
7,578,791	B2 8	3/2009	Rafter	2002/0198521		12/2002	
7,582,083			Swanson	2003/0013958			Govari et al.
7,585,310 7,610,073			Phan et al. Fuimaono et al.	2003/0088240 2003/0158548		5/2003 8/2003	Phan et al.
7,648,462			Jenkins et al.	2003/0158549			Swanson
7,697,972	B2 4	4/2010	Verard et al.	2003/0229286	A1	12/2003	Lenker
7,704,208	B2 4	4/2010	Thiele	2004/0006268	A1	1/2004	Gilboa et al.

### US 9,757,191 B2

Page 4

(56)	Referei	ices Cited	2009/006279			Malchano et al.
U.S	. PATENT	DOCUMENTS	2009/006279 2009/007639			Vakharia et al. Lee et al.
			2009/009381			
2004/0082860 A1	4/2004	Haissaguerre	2009/009381			Koblish et al.
2004/0092806 A1	5/2004	Sagon et al.	2009/009947			Remmert et al.
2004/0116793 A1	6/2004		2009/013193 2009/016390			Vakharia et al. Miller et al.
2004/0147920 A1		Keidar	2009/010390			Pope et al.
2004/0162556 A1 2004/0186467 A1	8/2004	Swanson Swanson et al.	2009/017134			
2004/0180407 A1 2004/0210136 A1		Varghese et al.	2009/017706			Razavi
2004/0215177 A1		Swanson	2009/017711	1 A		
2004/0215186 A1	10/2004	Cornelius et al.	2009/018231			
2005/0033331 A1		Burnett et al.	2009/020995 2009/021612			Starksen Lenker
2005/0059862 A1	3/2005		2009/021012			Rioux et al.
2005/0059962 A1 2005/0059963 A1		Phan et al. Phan et al.	2009/025927			Simon et al.
2005/0059965 A1		Eberl et al.	2009/027582	7 A	1 11/2009	Aiken et al.
2005/0065506 A1	3/2005		2009/028154			
2005/0065508 A1		Johnson et al.	2009/028720			
2005/0070894 A1		McClurken	2009/029220 2009/029935			Hadjicostis Bencini et al.
2005/0090817 A1	4/2005		2009/029936			
2005/0119545 A1 2005/0119648 A1		Swanson Swanson	2009/030664			Pappone et al.
2005/0119649 A1		Swanson	2010/001048	7 A		Phan et al.
2005/0119653 A1		Swanson	2010/005707			Roman et al.
2005/0119654 A1	6/2005	Swanson et al.	2010/007640			Mazzone et al.
2005/0124881 A1		Kanai et al.	2010/009427 2010/010615			Narayan et al.
2005/0187544 A1		Swanson et al.	2010/010013			Anderson et al. Park et al.
2005/0203597 A1 2005/0228286 A1		Yamazaki et al. Messerly et al.	2010/011555			Brunnett et al.
2005/0228504 A1 2005/0228504 A1		Demarais	2010/015272			Park et al.
2005/0273060 A1		Levy et al.	2010/016855			Deno et al.
2006/0030919 A1		Mrva et al.	2010/016856			
2006/0089634 A1		Anderson et al.	2010/016857			Sliwa et al.
2006/0100522 A1		Yuan et al.	2010/016883 2010/024111			Korivi et al. Paul et al.
2006/0161146 A1 2006/0247607 A1		Cornelius et al. Cornelius et al.	2010/024111			Hastings et al.
2006/0247683 A1		Danek et al.	2010/024960		1 9/2010	Hastings et al.
2006/0253028 A1		Lam et al.	2010/024960	4 A	1 9/2010	Hastings et al.
2006/0253116 A1	11/2006	Avitall et al.	2010/029882			Leo et al.
2007/0003811 A1		Zerfass et al.	2010/033165			Kim et al. Lau et al.
2007/0016054 A1		Yuan et al	2011/002882 2011/003491			Ibrahim et al.
2007/0016059 A1 2007/0016228 A1	1/2007	Morimoto et al.	2011/007140			Hastings et al.
2007/0010228 A1 2007/0021744 A1		Creighton	2011/007140		1 3/2011	Hastings et al.
2007/0049925 A1		Phan et al.	2011/011256			Friedman et al.
2007/0055225 A1	3/2007	Dodd, III et al.	2011/012514			Gross et al.
2007/0073135 A1		Lee et al.	2011/013064 2011/013715			Beeckler et al. Govari et al.
2007/0088345 A1		Larson et al.	2011/013/13			Sliwa et al.
2007/0165916 A1 2007/0167813 A1	7/2007	Cloutier et al. Lee et al.	2011/014452			Fish et al.
2007/0181139 A1		Hauck	2011/016058			Paul et al.
2007/0238997 A1	10/2007	Camus	2011/023793			
2007/0270794 A1		Anderson et al.	2011/028224 2011/031978			Tsoref et al. Sweeney et al.
2008/0009733 A1		Saksena	2012/000454			Harks et al.
2008/0015568 A1 2008/0025145 A1		Paul et al. Peszynski et al.	2012/009534			Adam et al.
2008/0023143 A1 2008/0051841 A1		Swerdlow et al.	2012/010139		1 4/2012	Ramanathan et al.
2008/0058836 A1		Moll et al.	2012/011653			Liebetanz
2008/0086073 A1		McDaniel	2012/013634			Condie et al.
2008/0091109 A1		Abraham	2012/013634 2012/013635			Condie et al. Weekamp et al.
2008/0140065 A1 2008/0161705 A1		Rioux et al.	2012/017269			Hastings et al.
2008/0161703 A1 2008/0161795 A1		Podmore et al. Wang et al.	2012/017272			Hastings et al.
2008/0161796 A1		Cao et al.	2012/017287		1 7/2012	Hastings et al.
2008/0195089 A1		Thiagalingam et al.	2012/023889			Wilfley et al.
2008/0228111 A1			2012/031006			
2008/0243214 A1		Koblish	2012/033030 2013/002378			Vegesna et al. Schneider et al.
2008/0275428 A1 2008/0281322 A1	11/2008	Tegg et al. Sherman et al.	2013/002389			Wallace
2008/0287803 A1		Li et al.	2013/006024			Grunewald et al.
2008/0300454 A1			2013/006631			Subramaniam et al.
2008/0312521 A1		Solomon	2013/006631	5 A	1 3/2013	Subramaniam et al.
2008/0312713 A1		Wilfley et al.	2013/007976			Heckel et al.
2009/0005771 A1		Lieber et al.	2013/016592			Mathur et al.
2009/0030312 A1		Hadjicostis	2013/017271			Just et al.
2009/0048591 A1		Ibrahim et al.	2013/017274			Rankin et al. Govari et al.
2009/0056344 A1	3/2009	r och	2013/017287	ЭΑ	1/2013	Govan et al.

(56) References Cited				JP	2015501162 A	1/2015
US	PATENT	Γ DOCUMENTS		JP KR	2015509027 A 20100021401 A	3/2015 2/2010
0.0	. 171112111	DOCOMENTO		KR	101490374 B1	2/2015
2013/0184706 A1		Gelbart et al.		WO WO	WO9221278 A1 WO9413358 A1	12/1992 6/1994
2013/0190747 A1 2013/0197363 A1		Koblish et al. Rankin et al.		wo	WO9725916 A1	7/1997
2013/0226169 A1	8/2013	Miller et al.		WO	WO9725917 A1	7/1997
2013/0274582 A1		Afonso et al. Gertner		WO WO	WO9736541 A1 1997045156 A2	10/1997 12/1997
2013/0331739 A1 2014/0012251 A1		Himmelstein et al.		WO	WO9858681 A2	12/1998
2014/0058375 A1		Koblish		WO WO	9909879 A1 WO9927862 A1	3/1999 6/1999
2014/0066764 A1 2014/0073893 A1		Subramaniam et al. Bencini		wo	WO0029062 A2	5/2000
2014/0075753 A1		Haarer et al.		WO	WO0158372 A1	8/2001
2014/0081111 A1		Tun et al.		WO WO	WO0164145 A1 WO0168173 A2	9/2001 9/2001
2014/0081112 A1 2014/0081113 A1		Kim et al. Cohen et al.		WO	WO0205868 A2	1/2002
2014/0081262 A1	3/2014	Koblish et al.		WO WO	WO0209599 A2 WO0219934 A1	2/2002 3/2002
2014/0107453 A1 2014/0107636 A1		Maskara et al. Bencini		WO	WO0213334 A1 WO0247569 A1	6/2002
2014/0194867 A1	7/2014	Fish et al.		WO	WO02102234 A2	12/2002
2014/0214028 A1		Gelbart et al.		WO WO	WO03039338 A2 WO2007079278 A1	5/2003 7/2007
2014/0228713 A1 2014/0243917 A1	8/2014	Thao et al. Morley et al.		WO	WO2008046031 A2	4/2008
2014/0261985 A1	9/2014	Selkee		WO WO	WO2008118992 A1 WO2009032421 A2	10/2008 3/2009
2014/0276052 A1 2014/0276811 A1		Rankin et al. Koblish et al.		WO	2009048824 A1	4/2009
2014/0364843 A1	12/2014	Paul et al.		WO	2009048943 A	4/2009
2014/0364848 A1		Heimbecher et al.		WO WO	2010054409 A1 WO2010056771 A1	5/2010 5/2010
2015/0133914 A1 2015/0133920 A1		Koblish Rankin et al.		WO	2010082146 A1	7/2010
2015/0265341 A1	9/2015	Koblish		WO WO	2011008444 A1	1/2011
2015/0265348 A1 2015/0342672 A1		Avitall et al. Bencini et al.		WO	2011033421 A1 WO2011024133 A1	3/2011 3/2011
2015/0374436 A1		Subramaniam et al.		WO	WO2011089537 A1	7/2011
2016/0100884 A1	4/2016	Fay et al.		WO WO	2011101778 A1 WO2011095937 A1	8/2011 8/2011
EODE.	GNI DATE	ENT DOCUMENTS		WO	2012001595 A1	1/2012
TOKE.	ONTAIL	INT DOCUMENTS		WO WO	WO2012001595 A1 WO2012049621 A1	1/2012 4/2012
	48053 A1	3/2013		WO	WO2012049021 A1 WO2012066430 A1	5/2012
	69703 A 55655 A	10/2000 11/2003		WO	2012161880 A1	11/2012
CN 19	42145 A	4/2007		WO WO	WO2012151301 A1 2012166239 A1	11/2012 12/2012
	71607 A 73986 A	12/2011 7/2012		WO	2013040201 A2	3/2013
	17185 A	7/2012		WO WO	2013040297 A1 2014072879 A2	3/2013 5/2014
	87336 A	8/2014		wo	2014152575 A2	9/2014
	19259 A 40513 A	5/2015 5/2015		WO	2015143061 A1	9/2015
CN 1046	61609 A	5/2015		WO	2015183635 A1	12/2013
EP 1343426 B1 9/2003 EP 1343427 B1 9/2003					OTHER PU	BLICATIONS
EP 15	02542 A1	2/2005				
	47537 A1 85423 B1	6/2005 4/2006				ation of Ventricular Myocardium
EP 17	17601 A2	11/2006				ng Current: Bio-Physical Aspects CE, 12:187-195, Jan. 1989, Part II.
	35332 A2	6/2008		Internati	onal Preliminary Exar	nination Report issued in PCT/
	55587 A 55588 A	7/2014 7/2014			/060183, completed Ma	
EP 21	36702 B1	7/2015			/056211, completed Feb	t on Patentability issued in PCT/ 24, 2015, 5 pages.
	00242 A 83918 A	1/2000 3/2000				t on Patentability issued in PCT/
JP 20005	04242 A	4/2000			/060194, mailed Mar. 2-	
	28039 A 04090 A	8/2002			onal Search Report and 058324, dated Aug. 18	Written Opinion issued in PCT/
	03335 A	2/2003 2/2004				Written Opinion issued in PCT/
JP 20062	39414 A	9/2006		US2012	/055309, mailed Nov. 1	9, 2012, 13 pages.
	63559 A 44857 A	6/2007 9/2007				Written Opinion issued in PCT/
JP 20091	42653 A	12/2008			/056211, mailed Jan. 20 onal Search Report and	Written Opinion issued in PCT/
	18150 A 22623 A	5/2009 7/2010		US2013	/060183, mailed Jan. 27	, 2014, 10 pages.
JP 20111	42995 A	7/2010				Written Opinion issued in PCT/
JP 20115	25842 A	9/2011			/060194, mailed Jan. 29 onal Search Report and	, 2014. I Written Opinion issued in PCT/
	31967 A 36465 B2	12/2012 11/2013			/060194, mailed Jan. 29	•
JP 20140	12174 A	1/2014		Internati	onal Search Report and	Written Opinion issued in PCT/
JP 20145	31244 A	11/2014		US2015	/021300, mailed Jun. 9,	2015, 11 pages.

### (56) References Cited

### OTHER PUBLICATIONS

International Search Report and Written Opinion issued in PCT/US2015/031591, mailed Aug. 17, 2015, 11 pages.

Machi MD, Junji, "Prevention of Dispersive Pad Skin Burns During RFA by a Simple Method", Editorial Comment, Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 372-373.

Neufeld, Gordon R. et al., "Electrical Impedance Properties of the Body and the Problem of Alternate-site Burns During Electrosurgery", Medical Instrumentation, vol. 19, No. 2, Mar.-Apr. 1985, pp. 83-87.

Partial International Search Report issued in PCT/US2012/055155, mailed Dec. 20, 2012, 7 pages.

Pires, L. A., et. al. Temperature-guided Radiofrequency Catheter Ablation of Closed-Chest Ventricular Myocardium with a Novel Thermistor-Tipped Catheter. American Heart Journal, 127(6):1614-1618, Jun. 1994.

Ring, E. R., et. al. Catheter Ablation of the Ventricular Septum with Radiofrequency Energy. American Heart Journal, 117(6):1233-1240. Jun. 1989.

Steinke, Karin et al., "Dispersive Pad Site burns With Modern Radiofrequency Ablation Equipment", Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 366-371.

Extended European Search Report issued in EP Application No. 15174537.9, issued Mar. 2, 2016, 7 pages.

International Preliminary Examination Report issued in PCT/US2013/060612, completed Mar. 24, 2015, 10 pages.

International Preliminary Report on Patentability issued in PCT/US2008/058324, mailed Sep. 29, 2009, 9 pages.

International Preliminary Report on Patentability issued in PCT/US2012/055155, issued Mar. 18, 2014, 11 pages.

International Preliminary Report on Patentability issued in PCT/US2012/055309, issued on Mar. 18, 2014, 8 pages.

International Preliminary Report on Patentability issued in PCT/US2013/058105, completed Mar. 10, 2015.

International Preliminary Report on Patentability issued in PCT/US2014/027491, mailed Sep. 24, 2015, 12 pages.

International Search Report and Written Opinion issued in PCT/US2012/031819, mailed Sep. 27, 2012, 16 pages.

International Search Report and Written Opinion issued in PCT/US2012/055155, mailed Mar. 11, 2013, 19 pages.

International Search Report and Written Opinion issued in PCT/US2012/072061, mailed Mar. 21, 2013, 9 pages.

International Search Report and Written Opinion issued in PCT/US2013/020503, mailed Mar. 20, 2013, 10 pages.

International Search Report and Written Opinion issued in PCT/US2013/058105, mailed Nov. 22, 2013, 16 pages.

International Search Report and Written Opinion issued in PCT/US2013/060612, mailed Feb. 28, 2014, 16 pages.

International Search Report and Written Opinion issued in PCT/US2014/027491, mailed Sep. 23, 2014, 17 pages.

International Search Report and Written Opinion issued in PCT/US2015/055173, mailed Jan. 18, 2016, 11 pages.

International Search Report and Written Opinion issued in PCT/US2015/057242, mailed Jan. 15, 2016, 11 pages.

Invitation to Pay Additional Fees and Partial International Search Report issued in PCT/US2014/027491, mailed Jul. 28, 2014, 5 pages.

Patriciu, A. et al., "Detecting Skin Burns Induced by Surface Electrodes", published in Engineering in Medicine and Biology Society, 2001. Proceedings of the 23rd Annual International Conference of the IEEE, vol. 3, pp. 3129-3131.

International Search Report and Written Opinion issued in PCT/US2013/021013, mailed Apr. 5, 2013, 14 pages.

Piorkowski, Christopher et al., "First in Human Validation of Impedance-Based Catheter Tip-to-Tissue Contact Assessment in the Left Atrium", Journal of Cardiovascular Electrophysiology, vol. 20, No. 12, Dec. 1, 2009, pp. 1366-1373.

Price, Adam et al., "Novel Ablation Catheter Technology that

Price, Adam et al., "Novel Ablation Catheter Technology that Improves Mapping Resolution and Monitoring of Lesion Maturation", The Journal of Innovations in Cardiac Rhythm Management, vol. 3, 2002, pp. 599-609.

Price, Adam et al., "PO3-39 Pin Electrodes Improve Resolution: Enhanced Monitoring of Radiofrequency Lesions in the Voltage and Frequency Domains", Heart Rhythm 2010, 31st Annual Scientific Sessions, May 12-15, in Denver Colorado.

Zachary, J.M. et al., "PO4-86 Pin Electrodes Provide Enhanced Resolution Enabling Titration of Radiofrequency Duration to Lesion Maturation", Heart Rhythm 2011, 32 Annual Scientific Sessions, May 4-7, San Francisco, CA.


Extended European Search Report issued in EP Application 16182627.6, mailed Nov. 8, 2016, 5 pages.


International Preliminary Report on Patentability issued in PCT/US2015/021300 mailed Sep. 29, 2016, 7 pages.


International Search Report and Written Opinion issued in PCT/US2015/066874, mailed Apr. 1, 2016, 11 pages.

International Search Report and Written Opinion issued in PCT/US2016/028006 mailed Jul. 12, 2016, 12 pages.


International Preliminary Report on Patentability issued in PCT/US2015/031591, mailed Dec. 6, 2016, 7 pages.









o E















FIG. 8












**H**6.3






FIG. 14




FIG. 15

## ELECTROPHYSIOLOGY SYSTEM AND METHODS

### CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. application Ser. No. 13/738,562 filed Jan. 10, 2013, which claims the benefits of Provisional Application No. 61/715,032, filed Oct. 17, 2012, and Provisional Application No. 61/585,083 filed <sup>10</sup> Jan. 10, 2012, each of which are incorporated herein by reference in their entirety.

#### TECHNICAL FIELD

The present disclosure relates to therapies for cardiac conditions. More particularly, the present disclosure relates to methods and systems for ablation of cardiac tissue for treating cardiac arrythmias.

### **BACKGROUND**

Aberrant conductive pathways disrupt the normal path of the heart's electrical impulses. For example, conduction blocks can cause the electrical impulse to degenerate into 25 several circular wavelets that disrupt the normal activation of the atria or ventricles. The aberrant conductive pathways create abnormal, irregular, and sometimes life-threatening heart rhythms called arrhythmias. Ablation is one way of treating arrhythmias and restoring normal contraction. The 30 sources of the aberrant pathways (called focal arrhythmia substrates) are located or mapped using mapping electrodes situated in a desired location. After mapping, the physician may ablate the aberrant tissue. In radio frequency (RF) ablation, RF energy is directed from the ablation electrode 35 through tissue to an electrode to ablate the tissue and form a lesion.

### **SUMMARY**

In Example 1, the present invention is an electrophysiology method comprising advancing a distal portion of an ablation catheter intravascularly to a location proximate myocardial tissue within a chamber of a heart. The distal portion of the ablation catheter includes a tissue ablation 45 electrode and a plurality of microelectrodes circumferentially distributed about the tissue ablation electrode and electrically isolated therefrom. The tissue ablation electrode is configured to apply ablation energy to the myocardial tissue, and the plurality of microelectrodes define a plurality 50 of bipolar microelectrode pairs, each bipolar microelectrode pair configured to generate an output signal. The method further comprises acquiring the output signals from each of the bipolar microelectrode pairs, and comparing an amplitude of the output signal from each of the bipolar micro- 55 electrode pairs to the amplitudes of the output signals from the other of the plurality of bipolar microelectrode pairs. The method further comprises displaying to a clinician a visual indication of a proximity of the tissue ablation electrode to the myocardial tissue. The visual indication includes an 60 indication that the tissue ablation electrode is in contact with the myocardial tissue if a difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals exceeds a predetermined threshold, an indication that the tissue ablation electrode is 65 not in contact with the myocardial tissue if the difference between the amplitude of any one of the output signals and

2

the amplitude of any one or more of the other output signals does not exceed a predetermined threshold.

In Example 2, the method of Example 1, wherein the acquiring and comparing steps are performed by a mapping processor operatively coupled to the microelectrodes.

In Example 3, the method of either of Examples 1 or 2, wherein the plurality of microelectrodes include three microelectrodes defining first, second and third bipolar microelectrode pairs.

In Example 4, the method of Example 3, wherein the three microelectrodes are disposed at the same longitudinal position along the tissue ablation electrode.

In Example 5, the method of any of Examples 1-4, further comprising displaying to the clinician a visual indication of an orientation of the tissue ablation electrode relative to the myocardial tissue based on the amplitudes of the output signals from the first, second and third bipolar microelectrode pairs.

In Example 6, of any of Examples 1-5, further comprising acquiring output signals from one or more ring electrodes located on the ablation catheter proximal to the tissue ablation electrode, comparing the output signal from each bipolar microelectrode pair with the ring electrode output signals to identify intrinsic cardiac activation signals in the bipolar microelectrode pair signals, and generating an output to a display indicating a gap in an ablation lesion set at the location of any bipolar microelectrode pairs that sensed the intrinsic cardiac activation signals.

In Example 7, the method of any of Examples 1-6, wherein the ablation catheter further comprises a plurality of irrigation ports in the tissue ablation electrode fluidly and operatively coupled to an irrigation fluid reservoir and pump.

In Example 8, the method of any of Examples 1-7, wherein the ablation catheter further includes a proximal handle having a control element for manipulation by a user, and wherein advancing the distal portion of the ablation catheter includes manipulating the control element to deflect the distal portion for positioning the tissue ablation electrode adjacent to the myocardial tissue.

In Example 9, an electrophysiology system comprising an ablation catheter, a radiofrequency (RF) generator, and a mapping processor. The ablation catheter includes a flexible catheter body having a distal portion, a tissue ablation electrode, and a plurality of microelectrodes. The tissue ablation electrode is configured to apply ablation energy to the myocardial tissue. The plurality of microelectrodes are circumferentially distributed about the tissue ablation electrode and electrically isolated therefrom, and define a plurality of bipolar microelectrode pairs, each bipolar microelectrode pair configured to generate an output signal. The RF generator is operatively coupled to the tissue ablation electrode for generating the ablation energy to be conveyed to the tissue ablation electrode. The mapping processor is configured to acquire the output signals from each of the bipolar microelectrode pairs, compare an amplitude of the output signal from each of the bipolar microelectrode pairs to the amplitudes of the output signals from the other of the plurality of bipolar microelectrode pairs, and generate an output to a display to provide a clinician with a visual indication of a proximity of the tissue ablation electrode to the myocardial tissue. The visual indication includes an indication that the tissue ablation electrode is in contact with the myocardial tissue if a difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals exceeds a predetermined threshold, and an indication that the tissue ablation electrode

is not in contact with the myocardial tissue if the difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals does not exceed a predetermined threshold.

In Example 10, the system of Example 9, wherein the 5 plurality of microelectrodes include three microelectrodes defining first, second and third bipolar microelectrode pairs.

In Example 11, the system of claim either of Examples 9 or 10, wherein the three microelectrodes are disposed at the same longitudinal position along the tissue ablation elec- 10

In Example 12, the system of any of Examples 9-11, wherein the mapping processor is further configured to generate an output to a display to provide the clinician with a visual indication of an orientation of the tissue ablation 15 electrode relative to the myocardial tissue based on the amplitudes of the output signals from the first, second and third bipolar microelectrode pairs.

In Example 13, the system of any of Examples 9-12, wherein the mapping processor is further configured to 20 acquire output signals from one or more ring electrodes located on the ablation catheter proximal to the tissue ablation electrode, compare the output signals from the bipolar microelectrode pairs with the ring electrode output signals to identify sensed intrinsic cardiac activation signals 25 in the bipolar microelectrode pair output signals, and generate an output to the display indicating a gap in an ablation lesion pattern at the location of the bipolar microelectrode pairs that sensed the intrinsic cardiac activation signals.

In Example 14, the system of any of Examples 9-13, 30 wherein the ablation catheter further comprises a plurality of irrigation ports in the tissue ablation electrode fluidly and operatively coupled to an irrigation fluid reservoir and

In Example 15, the system of any of Examples 9-14, 35 wherein the ablation catheter further includes a proximal handle having a control element for manipulation by a user. and wherein the distal portion of the ablation catheter is deflectable upon manipulation of the control element.

While multiple embodiments are disclosed, still other 40 embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in 45 nature and not restrictive.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic illustration of a radio frequency 50 (RF) ablation system 1 according to one embodiment of the present invention.

FIG. 2 is a schematic illustration showing a conventional ablation catheter on the left and an embodiment of a high-

FIG. 3 illustrates a comparison between changes in voltage (panel A) and frequency spectra (panel B) pre- and post-ablation for each of the catheters illustrated in FIG. 2.

FIG. 4 illustrates a comparison of measured signal ampli- 60 tude pre- and post-ablation during atrial tachycardia.

FIG. 5 is a schematic illustration showing the catheter of FIG. 2 oriented generally parallel to the surface of the cardiac tissue to be mapped and ablated.

FIGS. 6A and 6B illustrate the amplitudes of the cardiac 65 electrical signals sensed by the microelectrodes and also the ring electrodes on the catheter of FIG. 2.

FIG. 7 is a schematic illustration showing the catheter of FIG. 2 oriented generally perpendicular to the surface of the cardiac tissue to be mapped and ablated.

FIG. 8 illustrates the corresponding electrogram signals for the configuration of FIG. 7.

FIG. 9 is a flow chart illustrating a method for assessing a characteristic (e.g., tissue contact) of the tissue ablation electrode of the ablation catheter of FIG. 1 or 2 according to the various embodiments.

FIG. 10 illustrates an output from a plurality of bipolar microelectrode pairs that can be used by the system of FIG. 1 in a method for determining the tip location when far field noise is suspected.

FIG. 11 illustrates an output from a plurality of bipolar microelectrode pairs that can be used by the system of FIG. 1 in a method for discerning different tissue types as the catheter navigates between different cardiac structures.

FIG. 12 illustrates an output from a plurality of bipolar microelectrode pairs that can be used by the system of FIG. 1 in a method for identifying gaps in lesion sets based on a comparison of signals between the ablation electrodes and microelectrodes.

FIG. 13 illustrates an output from a plurality of bipolar microelectrode pairs that can be used by the system of FIG. 1 in a method for assessing electrogram attenuation during ablation.

FIGS. 14 and 15 illustrate exemplary electroanatomical maps generated using a catheter including high-resolution microelectrodes according to embodiments of the invention.

While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.

### DETAILED DESCRIPTION

FIG. 1 is a schematic illustration of a radio frequency (RF) ablation system 1 according to one embodiment of the present invention. As shown in FIG. 1, the system 1 includes an ablation catheter 2, an RF generator 3, and a mapping processor 4. The ablation catheter 2 is operatively coupled to both the RF generator 2 and the mapping processor 4, as will be described in greater detail herein. As further shown, the ablation catheter 2 includes a proximal handle 5 having a control knob 6, a flexible body having a distal portion including a plurality of ring electrodes 7, a tissue ablation electrode 8, and a plurality of mapping microelectrodes 9 (also referred to herein as "pin" electrodes) disposed within and electrically isolated from the tissue ablation electrode 8.

In various embodiments, the ablation catheter 2 is conresolution ablation catheter of the present disclosure on the 55 figured to be introduced through the vasculature of the patient, and into one of the chambers of the heart, where it can be used to map and ablate myocardial tissue using the microelectrodes 9 and the tissue ablation 8. Thus, the tissue ablation electrode 8 is configured to apply ablation energy to the myocardial tissue. In the illustrated embodiment, the ablation catheter 2 is steerable, such that the distal portion can be deflected (as indicated by the dashed outlines in FIG. 1) by manipulation of the control knob 6. In other embodiments, the distal portion of the ablation catheter 2 has a pre-formed shape adapted to facilitate positioning the tissue ablation electrode 8 and the microelectrodes 9 adjacent to specific target tissue. In one such embodiment, the pre-

formed shape is generally circular or semi-circular and is oriented in a plane transverse to the general direction of the catheter body.

In various embodiments, the microelectrodes 9 are circumferentially distributed about the tissue ablation electrode 5 8 and electrically isolated therefrom. The microelectrodes 9 can be configured to operate in unipolar or bipolar sensing modes. In various embodiments, the plurality of microelectrodes 9 define a plurality of bipolar microelectrode pairs, each bipolar microelectrode pair being configured to gener- 10 ate an output signal corresponding to a sensed electrical activity of the myocardial tissue proximate thereto. The generated output signals from the microelectrodes 9 can be sent to the mapping processor 4 for processing as described

Exemplary catheters that can be used as the ablation catheter 2 can include those described in U.S. Patent App. Pub. Nos. US200810243214 entitled "High Resolution Electrophysiology Catheter," and 2010/0331658, entitled "Map and Ablate Open Irrigated Hybrid Catheter," which 20 are hereby incorporated by reference in their entireties for all purposes. In various exemplary embodiments, the tissue ablation electrode 8 can have a length of between 6 and 14 mm, and a plurality of microelectrodes 9 equally spaced about the circumference of the tissue ablation electrode. In 25 one embodiment, the tissue ablation electrode 8 can have an axial length of about 8 mm. In one embodiment, the ablation catheter 2 includes at least three microelectrodes 9 equally spaced about the circumference of the tissue ablation electrode 8 and at the same longitudinal position along the 30 longitudinal axis of the tissue ablation electrode 8, the microelectrodes 9 forming at least first, second and third bipolar microelectrode pairs. In one embodiment, the catheter 2 includes a forward-facing microelectrode 9 generally centrally-located within the tissue ablation electrode 8. An 35 exemplary such RF ablation catheter is illustrated in FIGS. 3 and 4 of the aforementioned U.S. Patent Application Pub. No. 2008/0243214.

In some embodiments, microelectrodes 9 can be located at other positions along the ablation catheter 2 in addition to 40 or in lieu of the microelectrodes 9 in the tissue ablation electrode 8.

In various embodiments, the tissue ablation electrode 8 has an exterior wall that defines an open interior region (not shown). The exterior wall includes mapping electrode open- 45 ings for accommodating the microelectrodes 9, and, in some embodiments, irrigation ports (not shown). The irrigation ports, when present, are in fluid communication an external irrigation fluid reservoir and pump (not shown) for supplying irrigation fluid to the myocardial tissue being mapped 50 and/or ablated. Exemplary irrigated catheters for use as the catheter 2 can be any of the catheters described in the aforementioned U.S. Patent App. Pub. No. 2010/0331658. In various embodiments, the catheter system may also microelectrodes 9 are electrically insulated from the exterior wall by the noise artifact isolators.

In various embodiments, the mapping processor 4 is configured to detect, process, and record electrical signals within the heart via the ablation catheter 2. Based on these 60 electrical signals, a physician can identify the specific target tissue sites within the heart, and ensure that the arrhythmia causing substrates have been electrically isolated by the ablative treatment. The mapping processor 4 is configured to process the output signals from the microelectrodes 9 and/or 65 the ring electrodes 7, and to generate an output to a display (not shown) for use by the physician. In some embodiments,

the display can include electrocardiograms (ECG) information, which can be analyzed by the user to determine the existence and/or location of arrhythmia substrates within the heart and/or determine the location of the ablation catheter 2 within the heart. In various embodiments, the output from the mapping processor 4 can be used to provide, via the display, an indication to the clinician about a characteristic of the ablation catheter 2 and/or the myocardial tissue being mapped.

The RF generator 3 is configured to deliver ablation energy to the ablation catheter 2 in a controlled manner in order to ablate the target tissue sites identified by the mapping processor 4. Ablation of tissue within the heart is well known in the art, and thus for purposes of brevity, the RF generator 3 will not be described in further detail. Further details regarding RF generators are provided in U.S. Pat. No. 5,383,874, which is expressly incorporated herein by reference. Although the mapping processor 4 and RF generator 3 are shown as discrete components, they can alternatively be incorporated into a single integrated device.

The RF ablation catheter 2 as described may be used to perform various diagnostic functions to assist the physician in an ablation treatment. For example, in some embodiments, the catheter is used to ablate cardiac arrhythmias, and at the same time provide real-time assessment of a lesion formed during RF ablation. Real-time assessment of the lesion may involve any of monitoring surface and/or tissue temperature at or around the lesion, reduction in the electrocardiogram signal, a drop in impedance, direct and/or surface visualization of the lesion site, and imaging of the tissue site (e.g., using computed tomography, magnetic resonance imaging, ultrasound, etc.). In addition, the presence of the microelectrodes within the RF tip electrode can operate to assist the physician in locating and positioning the tip electrode at the desired treatment site, and to determine the position and orientation of the tip electrode relative to the tissue to be ablated.

FIG. 2 is a schematic illustration showing a conventional ablation catheter 10 (i.e., an ablation catheter lacking any microelectrodes within the tissue ablationelectrode) on the left and an embodiment of a high-resolution ablation catheter 100 of the present disclosure on the right. For cardiac mapping, the conventional catheter relies on conventional ring electrodes 12, 14, 16 disposed along the mapping electrodes a distance from the ablation tip electrode 18, resulting in a large distance between the center of mapping/ pacing and the center of ablation. The catheter of the present disclosure, in contrast, includes the mapping microelectrodes 110 in mapping electrode openings 114 in the ablation tip electrode 118 to allow the center of mapping/pacing to be in substantially the same location as the center of ablation.

FIG. 3 illustrates a comparison between changes in voltinclude noise artifact isolators (not shown), wherein the 55 age (panel A) and frequency spectra (panel B) pre- and post-ablation for each of the catheters illustrated in FIG. 2. As is shown, the tip-to-ring signal changes in the conventional ablation catheter were minimal for both the voltage and frequency domains (arrows A and B). In contrast, the recorded changes from pin to pin (i.e., between mapping micro electrodes) in the catheter of the present disclosure were profound (arrows C and D).

> FIG. 4 illustrates a comparison of measured signal amplitude pre- and post-ablation during atrial tachycardia. As shown, the tip-to-ring again signal changes in the conventional ablation catheter (top arrows) were small compared to the pin-to-pin signal changes. Thus, the pin electrodes were

much more successful in identifying viable tissue responsible for the formation of gaps and the induction of atrial tachycardias.

As explained previously, the microelectrodes 110 can advantageously provide feedback on electrode contact and  $\,^{5}$ tip electrode orientation within the heart. FIG. 5 is a schematic illustration showing the catheter 100 oriented generally parallel to the surface 200 of the cardiac tissue to be mapped and ablated. FIGS. 6A and 6B illustrate the amplitudes of the cardiac electrical signals sensed by the microelectrodes 110 and also the ring electrodes on the catheter 100, which data can be used to implement a method for determining electrode contact and the orientation of the catheter tip. In FIGS. 6A and 6B, the ECG traces of bipolar pairs of microelectrodes 110 are illustrated, as indicated by the labels defined and their corresponding ECG signals are illustrated. Specifically, in FIG. 6A, an ablation catheter having four microelectrodes (labeled 49, 50, 51 and 52) distributed about the circumference of the tissue ablation 20 electrode, such that the labels 49-50, 50-51, 51-52 and 49-52 designate respective bipolar microelectrode pairs of adjacent microelectrodes. Similarly, in the example shown in FIG. **6**B, the ECG traces for three bipolar microelectrode pairs (labeled Q1-Q2, Q2-Q3, and Q3-Q4) are illustrated.

In the illustrated example, as shown in FIG. 6A, two bipolar microelectrode pairs (indicated by references 210, 220) each show a distinct atrial signal while the other bipolar microelectrode pairs (indicated by references 230, 240) show minimal amplitude. The mapping microelectrode(s) with a signal of minimal amplitude indicates floating in blood, which is suggestive of a parallel tip orientation. FIG. 6B illustrates a similar result, with two of the bipolar microelectrode microelectrode pairs (the pairs Q1-Q2 and Q2-Q3) showing an atrial signal and one pair (Q3-Q4) 35 showing a minimal signal amplitude. This data allows the system 1 to confirm both tip contact with the cardiac tissue as well as orientation of the tip relative to the tissue surface, which could not be accomplished using only the ring electrodes on the catheter 100, all of which show minimal signal 40 amplitude (as shown in FIGS. 6A and 6B) suggesting no tissue contact.

FIG. 7 is a schematic illustration showing the catheter 100 oriented generally perpendicular to the surface 200 of the cardiac tissue to be mapped and ablated, and FIG. 8 illustrates the corresponding electrogram signals for the configuration of FIG. 7. As can be seen in FIG. 8, all bipolar microelectrode pairs (designated by R3-R1, R2-R3 and R1-R2) show substantially equal signal amplitude, indicating that all of the microelectrodes are floating in blood and 50 not in contact with the surface 200.

FIG. 9 is a flow chart illustrating a method 250 for assessing a characteristic (e.g., tissue contact) of the tissue ablation electrode of the ablation catheter 2, 100 according to the various embodiments as described herein. As shown 55 in FIG. 9, the method 250 includes, at step 255, first advancing the distal portion of the ablation catheter intravascularly to a location proximate the myocardial tissue to be mapped and/or ablated. The ablation catheter may be the ablation catheter 2 or 100 described herein. In the various 60 embodiments, the particular ablation catheter includes a plurality of microelectrodes in the tissue ablation electrode defining a plurality of bipolar pairs of microelectrodes. In one embodiment, the ablation catheter includes at least three microelectrodes disposed about the circumference of the 65 tissue ablation electrode defining first, second and third bipolar microelectrode pairs.

R

Next, at step 260, the system acquires the output signal from each bipolar electrode pair. Subsequently, as shown at step 265, the method compares the amplitude of the output signal from each of the bipolar microelectrode pairs to the amplitudes of the output signals from the other of the plurality of bipolar microelectrode pairs. Then, as indicated at step 70, a display is generated indicating a condition of the tissue ablation electrode relative to the myocardial tissue based on differences between amplitudes of output signals.

In one embodiment, the displayed condition can include a visual indication of the proximity of the tissue ablation electrode to the myocardial tissue. In one embodiment, this visual indication of proximity can include an indication that the tissue ablation electrode is in contact with the myocardial tissue if the difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals exceeds a predetermined threshold. In addition, the visual indication of proximity can include an indication that the tissue ablation electrode is not in contact with the myocardial tissue if the difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals does not exceed a predetermined threshold.

In various embodiments, the steps of acquiring and com-25 paring the output signals from the bipolar microelectrode pairs are performed by the mapping processor, which is operatively coupled to the microelectrodes (see FIG. 1).

In one embodiment, the microelectrodes, and consequently, the first, second and third bipolar microelectrode pairs, each have a known position with respect to the tissue ablation electrode and the other microelectrodes. In such embodiments, the method 250 can further include displaying to the clinician a visual indication of the orientation of the tissue ablation electrode relative to the myocardial tissue based on the amplitudes of the output signals from the first, second and third bipolar microelectrode pairs.

In one embodiment, the method 250 can be carried out using an irrigated ablation catheter having a plurality of irrigation ports in the tissue ablation electrode fluidly and operatively coupled to an irrigation fluid reservoir and pump, and the method 250 includes supplying an irrigation fluid through the irrigation ports during the mapping and/or ablation procedures.

Still other methods may advantageously be facilitated by the presence and configurations of the microelectrodes of the ablation catheters 2, 100 described herein. For example, FIG. 10 illustrates an ECG generated from an output from a plurality of bipolar microelectrode pairs (labeled 49-50, 50-51, 51-52 and 49-52, respectively) that can be used by the system 1 in a method for determining the tip location when far field noise is suspected. In the example shown, the microelectrodes located at the tissue ablation electrode only pick up a ventricular signal, indicating the tissue ablation catheter is in the ventricle. On the other hand, the ring electrodes pick up both atrial and ventricular signals. Based on these signals, it may be determined that the ablation electrode is likely halfway through the tricuspid valve.

FIG. 11 illustrates an ECG generated from an output from a plurality of bipolar microelectrode pairs (labeled 49-50, 50-51, 51-52 and 49-52, respectively) that can be used by the system 1 in a method for discerning different tissue types as the catheter navigates between different cardiac structures. In the embodiment shown, the microelectrodes exhibit minimal response as the catheter is located within the superior vena cava. When the catheter exits the superior vena cava and enters the right atrium, the signals generated by the microelectrodes change substantially.

FIG. 12 illustrates an ECG generated from an output from a plurality of bipolar microelectrode pairs (labeled T1-T2, T2-T3, T3-T1, respectively) that can be used by the system 1 in a method for identifying gaps in lesion sets. In the example illustrated, the ablation electrodes pick up minimal 5 signals while the microelectrodes located at the tip of the ablation electrode picks up distinct atrial signals, indicating gaps in the lesion set. Thus, in an exemplary method, the mapping processor 4 can identify distinct intrinsic cardiac activation signals in the output signals from the bipolar microelectrode pairs, and thereafter generate an output to a display to identify the corresponding gaps in the lesion sets based on the locations of those bipolar microelectrode pairs. In various embodiments, the mapping processor 4 can further acquire output signals from the ring electrodes 7 (or 15 bipolar pairs defined by two ring electrodes 7 or a ring electrode 7 and the tissue ablation electrode 8) (see FIG. 1), compare the output signals from the bipolar microelectrode pairs to corresponding outputs from the ring electrodes, and use this comparison in identifying the intrinsic activation 20 signals and corresponding gaps in lesion sets.

FIG. 13 illustrates an ECG generated from an output from a plurality of bipolar microelectrode pairs (labeled 49-50, 50-51, 51-52 and 49-52, respectively) that can be used by the system 1 in a method for assessing electrogram attenuation 25 during ablation. In the illustrated example, the electrogram amplitude of the microelectrodes in contact with the tissue is greater than those in the blood. When the RF energy is turned on during ablation, the microelectrodes show a reduction in amplitude.

The microelectrode ablation catheters 2, 100 of the various embodiments can also advantageously be integrated with a three-dimensional cardiac mapping system for generating high-resolution electroanatomical maps of the heart for aiding the physician in diagnosing cardiac arrhythmias 35 (e.g., atrial fibrillation), identifying a treatment regime (e.g., ablation procedures such as pulmonary vein isolation) and verifying the sufficiency of the treatment. FIGS. 14 and 15 illustrate exemplary electroanatomical maps 300, 400, 500, 600. In FIG. 14, the map 300 is an exemplary dominant 40 frequency map generated using a conventional ablation catheter such as the catheter 10 in FIG. 2, and the map 400 is an exemplary dominant frequency map generated using the catheter 2 of FIG. 1 or the catheter 100 of FIG. 2 including the plurality of microelectrodes spatially located 45 within the RF ablation electrode. The particularly high signal fidelity provided by the mini-electrodes of the catheter 2, 100 allows the physician to accurately identify abnormal tissue substrates found in fibrotic tissue, thus allowing the physician to more readily discern different 50 tissue types and identify substrates to be ablated (e.g., by analysis of homogeneous or heterogeneous depolarization) than can be accomplished using the conventional ablation catheter 10 of FIG. 2. The advantages provided by the catheter 2, 100 is illustrated in FIG. 15, showing a compari- 55 son of electroanatomical maps generated by an exemplary conventional catheter 10 and the catheter 100 of the various embodiments on cardiac tissue confirmed by pathology to exhibit Type 1 fibrosis. As can be seen in FIG. 15 (left image), the map generated using the conventional catheter 60 10 showed normal voltage distribution within the fibrotic tissue. In contrast, the map generated using the catheter 2, 100 (right image) with the microelectrodes 9, 110 (FIGS. 1, 2 respectively) confirms abnormal voltages in the fibrotic

Various modifications and additions can be made to the exemplary embodiments discussed without departing from 10

the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.

We claim:

- 1. An electrophysiology method comprising:
- advancing a distal portion of an ablation catheter intravascularly to a location proximate myocardial tissue within a chamber of a heart, the distal portion of the ablation catheter including:
  - a tissue ablation electrode configured to apply ablation energy to the myocardial tissue;
  - a plurality of microelectrodes circumferentially distributed about the tissue ablation electrode and electrically isolated therefrom, the plurality of microelectrodes defining a plurality of bipolar microelectrode pairs, each bipolar microelectrode pair configured to generate an output signal based on a cardiac activation signal;

acquiring the output signals from each of the bipolar microelectrode pairs;

- comparing an amplitude of the output signal from each of the bipolar microelectrode pairs to the amplitudes of the output signals from the other of the plurality of bipolar microelectrode pairs; and
- displaying to a clinician a visual indication of a proximity of the tissue ablation electrode to the myocardial tissue, the visual indication including:
- an indication that the tissue ablation electrode is in contact with the myocardial tissue if, based on the comparison between the amplitudes of the output signals, a difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals exceeds a predetermined threshold; and
- an indication that the tissue ablation electrode is not in contact with the myocardial tissue if, based on the comparison between the amplitudes of the output signals, the difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals does not exceed a predetermined threshold.
- 2. The method of claim 1, wherein the acquiring and comparing steps are performed by a mapping processor operatively coupled to the microelectrodes.
- 3. The method of claim 1, wherein the plurality of microelectrodes include three microelectrodes defining first, second and third bipolar microelectrode pairs.
- **4**. The method of claim **3**, wherein the three microelectrodes are disposed at the same longitudinal position along the tissue ablation electrode.
- **5**. The method of claim **4**, further comprising displaying to the clinician a visual indication of an orientation of the tissue ablation electrode relative to the myocardial tissue based on the amplitudes of the output signals from the first, second and third bipolar microelectrode pairs.
- **6**. The method of claim **5**, wherein the ablation catheter further comprises a plurality of irrigation ports in the tissue ablation electrode fluidly and operatively coupled to an irrigation fluid reservoir and pump.
- 7. The method of claim 1, wherein the ablation catheter further includes a proximal handle having a control element for manipulation by a user, and wherein advancing the distal

portion of the ablation catheter includes manipulating the control element to deflect the distal portion for positioning the tissue ablation electrode adjacent to the myocardial tissue

8. An electrophysiology method comprising:

acquiring signals indicative of bioelectrical cardiac activity from bipolar pairs of microelectrodes of a plurality of microelectrodes, the plurality of microelectrodes circumferentially distributed around a tissue ablation electrode and electrically isolated therefrom, the tissue ablation electrode mounted on a catheter and configured to apply ablation energy to the myocardial tissue; comparing an amplitude of the signal from each of the bipolar microelectrode pairs to the amplitudes of the signals from the other of the plurality of bipolar microelectrode pairs; and

displaying to a clinician a visual indication of a proximity of the tissue ablation electrode to the myocardial tissue, the visual indication including:

an indication that the tissue ablation electrode is in contact with the myocardial tissue if, based on the comparison between the amplitudes of the output signals, a difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals exceeds a predetermined threshold; and

12

an indication that the tissue ablation electrode is not in contact with the myocardial tissue if, based on the comparison between the amplitudes of the output signals, the difference between the amplitude of any one of the output signals and the amplitude of any one or more of the other output signals does not exceed a predetermined threshold.

- **9**. The method of claim **8**, wherein the acquiring and comparing steps are performed by a mapping processor operatively coupled to the microelectrodes.
  - 10. The method of claim 8, wherein the plurality of microelectrodes include three microelectrodes defining first, second and third bipolar microelectrode pairs.
- 11. The method of claim 10, wherein the three microelectrodes are disposed at the same longitudinal position along the tissue ablation electrode.
- 12. The method of claim 11, further comprising displaying to the clinician a visual indication of an orientation of the tissue ablation electrode relative to the myocardial tissue based on the amplitudes of the output signals from the first, second and third bipolar microelectrode pairs.
- 13. The method of claim 8, wherein the ablation catheter further comprises a plurality of irrigation ports in the tissue ablation electrode fluidly and operatively coupled to an 25 irrigation fluid reservoir and pump.

\* \* \* \* \*



专利名称(译)	电生理学系统和方法					
公开(公告)号	<u>US9757191</u>	公开(公告)日	2017-09-12			
申请号	US14/498211	申请日	2014-09-26			
[标]申请(专利权)人(译)	波士顿科学西美德公司					
申请(专利权)人(译)	BOSTON SCIENTIFIC SCIMED INC.					
当前申请(专利权)人(译)	BOSTON SCIENTIFIC SCIMED , INC.					
[标]发明人	AVITALL BOAZ KOBLISH JOSEF V					
发明人	AVITALL, BOAZ KOBLISH, JOSEF V.					
IPC分类号	A61B18/12 A61B18/14 A61B18/18 A61B5/042 A61B5/00 A61B18/00 A61B5/06 A61B5/0464					
CPC分类号	A61B18/1492 A61B5/0422 A61B5/6852 A61B18/1206 A61B18/18 A61B5/0464 A61B5/065 A61B5 /4887 A61B2018/0016 A61B2018/00357 A61B2018/00577 A61B2018/00642 A61B2018/00654 A61B2018/00678 A61B2018/00839 A61B2018/00898 A61B2018/00904 A61B2018/00916 A61B2018 /126 A61B2218/002					
代理机构(译)	FAEGRE BAKER丹尼尔斯律师事务所					
审查员(译)	福勒,DANIEL					
优先权	61/715032 2012-10-17 US 61/585083 2012-01-10 US					
其他公开文献	US20150011995A1					
外部链接	Espacenet USPTO					
		ts a/mumsari	1.7 \$ 40000 17 1710000 170			

### 摘要(译)

电生理系统包括消融导管,射频发生器和映射处理器。消融导管具有组织消融电极和围绕组织消融电极的圆周分布并且与其电隔离的多个微电极。多个微电极限定多个双极微电极对。映射处理器被配置为从双极微电极对获取输出信号,比较输出信号,并产生输出到显示器,提供微电极和组织消融电极相对于待映射的心肌组织的特征的视觉指示。/或消融。

